Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Definium Therapeutics, Inc.

NASDAQ: DFTX · Life Sciences · 9 alerts · CIK 1813814

Share price
$30.16Close, Nov 16
Market cap
$4.13B
Shares outstanding
136.9MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Definium Therapeutics, Inc. filings on SEC EDGAR ↗

8:03 AM ET 8-K
Clinical Trial Data

Definium Therapeutics Clinical Trial Data

Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT for the treatment of generalized anxiety disorder (GAD). The study met its primary endpoint with a statistically significant reduction in HAM-A scores compared to placebo (p<0.0001) and was generally well tolerated. The company plans to file an NDA in the first half of 2027 following a pre-NDA meeting with the FDA in Q4 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.